Upper New York Chapter of AACE 2018 Annual Meeting

Fairport, NY US
October 20, 2018

Welcome, and thank you for attending the Upper New York Chapter of AACE 2018 Annual Meeting.

The Upper New York Chapter of AACE program committee has worked very hard to provide a relevant activity for the practicing clinical physician and other healthcare providers seeking education with an emphasis in endocrine disease.

This program has been planned to provide pertinent scientific and clinical information to help you achieve the best solutions in the diagnosis and therapeutic management of patients presenting with endocrine disease. Attendees will obtain updates in not only common and uncommon endocrine disorders, but also newer treatment modalities.

Providing exceptional patient care requires continuing high quality education. The American Association of Clinical Endocrinologists (AACE) was founded in 1991 by a visionary group of leaders to serve as the active voice for clinical endocrinologists. The impetus behind AACE's efforts has always been quality and cost-effective patient care for those with endocrine diseases and disorders. We hope that you will find this program of great value to you in your practice.

Program Syllabus

Target Audience

Endocrinologists, MDs/DOs, advanced practice clinicians, endocrine surgeons, and other health care professionals living in Upper New York.

Learning Objectives

  1. Determine clinical risk for cancer of thyroid nodules
  2. Understand ultrasonography risk for cancer in thyroid nodules
  3. FNA-understand procedure and limitations for diagnosing cancer
  4. Understand limitations of cytology in diagnosis of nodules when cytology yields indeterminate results-atypical lesions, follicular lesions
  5. Use of genomic sequencing classifiers (GSC) to identify patients with low risk of malignancy and surgical removal is not necessary
  6. If GSC positive for cancer-guide medical/surgical management
  7. When is lobectomy alone vs total thyroidectomy warranted?
  8. Understand when watchful waiting may be medically indicated
  9. Role of preoperative neck ultrasound, lymph node biopsy/surgery
  10. Identify goals of glucose management: what is too high, too low
  11. Understand the impact of glucose regulation in the hospital setting and impact on outcomes and length of stay
  12. Understand how metrics can guide performance quality initiative to improve glycemic control
  13. Systems of management for the hospitalized patient
  14. Limitations of SBGM amongst patients
  15. Understand the technologies now available to assess glycemic control and without finger stick testing
  16. HbA1C vs “time in range” and “time in hypoglycemia or hyperglycemia”-a new paradigm for assessing patients glycemic control
  17. Understand the role of glucagon inhibition and insulin secretory effects of analogues of our gut hormones
  18. Physiologic effects upon appetite, gastric motility and glucose dependent insulin secretion
  19. Effectiveness of this class of medication to reduce hyperglycemia, weight and insulin resistance
  20. The role of the kidney in glucose homeostasis
  21. The physiology of SGLT2i in glycemic management
  22. Clinical results using SGLT2i-glycemia, BP, weight and heart protection
  23. Articulate pharmacokinetic differences between the new long-acting basal insulin analogs
  24. Describe the efficacy (e.g., change in HbA1c, fasting plasma glucose) seen with the new long-acting basal insulin analogs
  25. Recognize the clinical utility, notably impact on hypoglycemia, with the new long-acting basal insulin analogs
Additional information
Available for MOC Points?: 
No
Practice Area: 
Diabetes
Course summary
Available credit: 
  • 5.75 AMA
  • 5.75 Attendance
Course opens: 
10/20/2018
Course expires: 
10/20/2019
Event starts: 
10/20/2018 - 7:15am
Event ends: 
10/20/2018 - 3:15pm
Cost:
$0.00

PROGRAM AGENDA

WOODCLIFF HOTEL
199 WOODCLIFF DR
FAIRPORT, NY 14450

Saturday, October 20, 2018

7:15 - 8:00 AM

Registration

8:00 – 8:15 AM

Introduction

Symposium: Nodular Thyroid Disease
8:15 – 8:45 AM

What Nodules Require FNA: Classification of at-risk nodules
Krishnakumar Rajamani, MD
Objectives

  1. Determine clinical risk for cancer of thyroid nodules
  2. Understand ultrasonography risk for cancer in thyroid nodules
  3. FNA-understand procedure and limitations for diagnosing cancer
8:45 – 9:15 AM

Genomic Testing (Molecular Testing): Assists in the management of patients with thyroid nodules of indeterminate testing on FNA cytology?
Ismat Shafiq, MD
Objectives

  1. Understand limitations of cytology in diagnosis of nodules when cytology yields indeterminate results-atypical lesions, follicular lesions
  2. Use of genomic sequencing classifiers (GSC) to identify patients with low risk of malignancy and surgical removal is not necessary
  3. If GSC positive for cancer-guide medical/surgical management
9:15 – 9:45 AM

Thyroid Surgery: Lobectomy, total thyroidectomy, LN biopsies or only watchful waiting?
Jacob Moalem, MD
Objectives

  1. When is lobectomy alone vs total thyroidectomy warranted?
  2. Understand when watchful waiting may be medically indicated
  3. Role of preoperative neck ultrasound, lymph node biopsy/surgery
9:45 – 10:15 AM

Q & A & Case Presentations

10:15 – 10:45 AM

Break

10:45 – 11:30 AM

Update on Inpatient Diabetes Management 
Marya Gendzielewski, MD; Grant Kelley, MD
Objectives

  1. Identify goals of glucose management: what is too high, too low
  2. Understand the impact of glucose regulation in the hospital setting and impact on outcomes and length of stay
  3. Understand how metrics can guide performance quality initiative to improve glycemic control
  4. Systems of management for the hospitalized patient
11:30 – 11:45 AM

Q & A

11:45 – 12:30 PM

Lunch/Business Meeting

Symposium: HbA1C Goals for Type 2 patients 2018 going forward:
How numbers may affect patient care
12:30 – 12:45 PM

Case Presentations

12:45 – 1:15 PM

CGMS: A paradigm shift for diabetes management
Michael Quartuccio, MD
Objectives

  1. Limitations of SBGM amongst patients
  2. Understand the technologies now available to assess glycemic control and without finger stick testing
  3. HbA1C vs “time in range” and “time in hypoglycemia or hyperglycemia”-a new paradigm for assessing patients glycemic control
1:15 – 1:45 PM

The GLP1-RA Class of Medications
Olga Astapova, MD, PhD; Luis Chavez, MD
Objectives

  1. Understand the role of glucagon inhibition and insulin secretory effects of analogues of our gut hormones
  2. Physiologic effects upon appetite, gastric motility and glucose dependent insulin secretion
  3. Effectiveness of this class of medication to reduce hyperglycemia, weight and insulin resistance
1:45 – 2:15 PM

The SGLT2i Class of Medications
Ajay Chaudhuri, MBBS, MRCP(UK), FACE
Objectives

  1. The role of the kidney in glucose homeostasis
  2. The physiology of SGLT2i in glycemic management
  3. Clinical results using SGLT2i-glycemia, BP, weight and heart protection
2:15 – 2:45 PM

New EDITION(s) and a BRIGHT Outlook DEVOTE(d) to DELIVER(ing) Improved Patient Care with Second-Generation Basal Insulin Analogs
Matthew Stryker, PharmD, BCACP, CLS
Objectives

  1. Articulate pharmacokinetic differences between the new long-acting basal insulin analogs
  2. Describe the efficacy (e.g., change in HbA1c, fasting plasma glucose) seen with the new long-acting basal insulin analogs
  3. Recognize the clinical utility, notably impact on hypoglycemia, with the new long-acting basal insulin analogs
2:45 – 3:15 PM

Q&A

3:15 PM

Wrap Up & Adjourn

WOODCLIFF HOTEL
199 WOODCLIFF DR
Fairport, NY 14450
United States

Olga Astapova, MD, PhD
Fellow, ABIM Research Pathway
University of Rochester Medical Center

Ajay Chaudhuri, MBBS, MRCP(UK), FACE
Professor of Medicine
University at Buffalo
Williamsville, NY 14032

Luis Chavez, MD
Endocrinology Fellow
University of Rochester
Rochester, NY

Marya Gendzielewski, MD
Attending, St. Joseph’s Health
Syracuse, NY

Grant Kelley, MD
Medical Quality Director
Informaticist
St Joseph’s Hospital Health Center
Syracuse, NY

Jacob Moalem, MD
Associate Professor
URMC
Rochester, NY

Michael Quartuccio, MD
Clinical Endocrinologist
Rochester Regional Health
Rochester, NY

Krishnakumar Rajamani, MD
Clinical Assistant Professor of Medicine
University of Rochester School of Medicine
Penfield, NY

Ismat Shafiq, MD
Associate Professor, Department of Medicine and Neurosurgery
University of Rochester
Rochester, NY

Matthew D. Stryker, PharmD, BCACP, CLS
Assistant Professor
Albany College of Pharmacy and Health Sciences
Albany, NY

Disclosure and Resolutions of Conflicts of Interest

The American Association of Clinical Endocrinologists remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of the American Association of Clinical Endocrinologists to eliminate all situations of potential conflict of interest, but rather to enable those who are working with the American Association of Clinical Endocrinologists to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the educational activity course director/chair to ensure that such situations are properly evaluated and, if necessary, resolved. The American Association of Clinical Endocrinologists educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all American Association of Clinical Endocrinologists CME activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities. All faculty and planning committee members are required to disclose any financial relationships and will be listed accordingly at aace.com.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Association of Clinical Endocrinologists (AACE) and the Upper New York Chapter of AACE. The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association of Clinical Endocrinologists (AACE) designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 5.75 AMA
  • 5.75 Attendance

Accreditation Period

Course opens: 
10/20/2018
Course expires: 
10/20/2019

Price

Cost:
$0.00
Please login or register to take this course.